Safety, Tolerability, PK, and PD Study of PGN-EDODM1 in Participants With Myotonic Dystrophy Type 1

PHASE1Active, not recruitingINTERVENTIONAL
Enrollment

24

Participants

Timeline

Start Date

December 12, 2023

Primary Completion Date

October 31, 2025

Study Completion Date

October 31, 2025

Conditions
Myotonic Dystrophy 1
Interventions
DRUG

PGN-EDODM1 for infusion

Single dose of PGN-EDODM1 by intravenous (IV) infusion

OTHER

Placebo

Administered by IV infusion

Trial Locations (12)

14642

University of Rochester Medical Center, Rochester

23298

Virginia Commonwealth University, Richmond

30329

Rare Disease Research, Atlanta

66205

University of Kansas Medical Center, Fairway

92697

UCI Center for Clinical Research, Irvine

94304

Stanford University, Palo Alto

02114

Massachusetts General Hospital, Boston

T3M 1M4

University of Calgary, Calgary

Unknown

Ottawa Hospital Research Institute (OHRI), Ottawa

CIUSSS du Saguenay-Lac-Saint-Jean, Chicoutimi

Salford Royal Hospital, Salford

NW1 2PG

University College London Hospital, London

Sponsors

Lead Sponsor

All Listed Sponsors
lead

PepGen Inc

INDUSTRY

NCT06204809 - Safety, Tolerability, PK, and PD Study of PGN-EDODM1 in Participants With Myotonic Dystrophy Type 1 | Biotech Hunter | Biotech Hunter